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tAnGo is a large randomised trial assessing the addition of gemcitabine(G) to paclitaxel(T), following epirubicin(E) and
cyclophosphamide(C) in women with invasive higher risk early breast cancer. To assess the safety and tolerability of adding G, a
detailed safety substudy was undertaken. A total of 135 patients had cardiac, pulmonary and hepatic function assessed at (i)
randomisation, (ii) mid-chemotherapy, (iii) immediately post-chemotherapy and (iv) 6 months post-chemotherapy. Skin toxicity was
assessed during radiotherapy. No differences were detected in FEV1 or FVC levels between treatment arms or time points. Diffusion
capacity (TLCO) reduced during treatment (Po0.0001), with a significantly lower drop in EC-GT patients (P¼0.02). Most of the
reduction occurred during EC and recovered by 6-months post treatment. There was no difference in cardiac function between
treatment arms. Only 11 patients had echocardiography/MUGA results change from normal to abnormal during treatment, with only
five having LVEFo50%. Transient transaminitis occurred in both treatment arms with significantly more in EC-GT patients post-
chemotherapy (AST P¼0.03, ALT P¼0.003), although the majority was low grade. There was no correlation between transaminitis
and other toxicities. Both treatment regimens reported temporary reductions in pulmonary functions and transient transaminitis
levels. Despite these being greater with EC-GT, both regimens appear well tolerated.
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Breast cancer deaths in the UK have declined 20–30% since the
late 1980s, despite an increasing incidence (41720 new cases
diagnosed in 2002). Increased use and improvement in systemic
adjuvant therapy have undoubtedly contributed to this reduced
mortality in the face of increasing incidence.
Combination chemotherapy has been shown to reduce recur-
rence rates when given after surgery to women at risk of relapse.
Anthracycline-based regimens are the standard of care throughout
the developed world reducing the breast cancer death rate ratios by
26–45% for younger and 17–24% for older women (EBCTCG,
2005). Modern anthracycline regimens appear to offer greater
improvement (B30% reduction in hazard ratio) over CMF (Levine
et al, 2005; Poole et al, 2006a). Block sequential chemotherapy
regimens have become standard in breast cancer after the
demonstration that sequence and timing were important
(Bonadonna et al, 2004).
The 1990s saw the initiation of many large randomised controlled
trials of taxanes in the adjuvant therapy of breast cancer. Results
from four first generation taxane trials are available and have
resulted in licensing of taxanes for the adjuvant treatment of node-
positive breast cancer. The addition of four cycles of paclitaxel after
four cycles of doxorubicin and cyclophosphamide reduces the risk
of recurrence by 17%, with manageable toxicity (Henderson et al,
2003; Mamounas et al, 2003), and became standard of care in the US
in the late 1990s, for higher risk node-positive patients.
Based on pre-clinical evidence of a potentially favourable
interaction between paclitaxel and gemcitabine (Kroep et al,
1999), as well as encouraging activity for gemcitabine in advanced
breast cancer (Carmichael et al, 1995; Blackstein et al, 1997;
Spielmann et al, 1997; Sanchez et al, 1998; Akrivakis et al, 1999;
Colomer et al, 2000), the tAnGo trial was initiated in the year 2000
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sto test the addition of gemcitabine to block sequential anthracy-
cline and paclitaxel adjuvant chemotherapy. The trial compared
EC-GT (four cycles of epirubicin 90mgm
 2 and cyclophospha-
mide 600mgm
 2 day 1 every (q) 3 weeks, followed by four cycles
of paclitaxel 175mgm
 2 every 3h infusion day 1 and gemcitabine
1250mgm
 2 days 1 and 8 q3 weeks) with EC-T. The primary end
point for the 3000 patient trial was disease-free survival (DFS),
aiming to prove a 5% improvement from 70% 5-year DFS.
In view of the unknown acute and long-term sequelae of
gemcitabine in combination with paclitaxel, radiation-sensitisation
properties of gemcitabine (McGinn et al, 1996) and concern about
the possibility of severe and/or delayed pulmonary (Gupta et al,
2002; Trodella et al, 2002; Maas et al, 2003) and hepatic toxicity
(Poole et al, 2006b), a detailed toxicity and tolerability surveillance
study was undertaken on an initial cohort of patients randomised
into tAnGo. Hepatic, cardiac and pulmonary function and all
adverse events (AEs) were monitored.
PATIENTS AND METHODS
All patients randomised into tAnGo were eligible for this detailed
safety substudy (DSS) until the accrual target had been met.
Patients underwent tests at four time points: (i) randomisation;
(ii) mid-chemotherapy (between cycles 4 and 5); (iii) immediately
post-chemotherapy and (iv) 6-months post-chemotherapy. Late
toxicity assessment included follow-up tests in the event of any
symptomatic deterioration, and also at 5 and 10 years post-
treatment. Results from the first four planned time points are
presented here.
Pulmonary function assessments comprised spirometry tests,
Forced Expiratory Volume in one second (FEV1, litres) as a
measure of airway obstruction and Forced Vital Capacity (FVC,
litres), single breath diffusion tests, measuring total lung capacity
(TLCO, mmolmin
 1kPa
 1) (locally corrected for Hb), and gas
diffusion of CO within lungs (KCO, mmolmin
 1kPa
 1l
 1). Cardiac
assessments comprised ECG tests and either echocardiograms or
MUGA (multi-gated acquisition) scans. Chest X-rays (CXR) were
also undertaken, as were hepatic function tests serum AST and
ALT. Radiotherapy acute skin toxicity treatment was collected
weekly.
This trial was approved by Multi-Research Ethics Committee
and conducted in accordance with the declaration of Helsinki.
STATISTICAL METHODS
Symptomatic pulmonary toxicity associated with single-agent
gemcitabine was estimated to be 1.6% (Sara et al, 2000). Assuming
a 1.5–2% incidence of symptomatic pulmonary toxicity, the
accrual of 65 patients from each treatment arm into the tAnGo DSS
would allow detection of a 10-fold difference in the risk of
symptomatic pulmonary toxicity relative to this, with an 80%
power at the 2-sided 5% level of significance.
FEV1 levels were categorised into normal, mild, moderate or
severe obstruction using British Thoracic Society’s COPD guide-
lines. ECGs, echocardiograms, MUGA scans and CXRs were
classed as normal or abnormal by clinicians. Hepatic function
was graded according to CTC toxicity criteria (version 2).
Radiotherapy acute skin toxicities were categorised by clinicians
into nil, mild, moderate or severe. Assessment times and treatment
arms were then compared using w
2 tests, Fisher’s exact tests or
generalised linear models where appropriate.
Random effects modelling was applied to FVC and TLCO levels
over time, and results presented graphically as patients’ raw scores,
percentages of patients’ baseline measures and the average patient
values over time for each treatment arm as predicted by the model.
Results were also categorised into low, normal or high levels
(Quanjer, 1993).
RESULTS
A total of 135 tAnGo patients (69 randomised to EC-GT, 66 to
EC-T) were entered into the DSS between August 2001 and October
2002. The DSS subgroup appeared balanced in terms of
randomised treatment and also balanced across randomised
treatment groups in terms of prognostic variables (Table 1).
However, when comparing the DSS group with other patients
randomised into tAnGo, the DSS group reported a smaller
proportion of ER and PgR positive tumours, a larger proportion
of HER2 positive tumours, higher nodal status, higher mastectomy
rates and worse tumour grades. These expected differences reflect
the change in tAnGo eligibility criteria, from ER-poor to any
hormone status, which was implemented after the first 550 patients
had been randomised, after the DSS had completed recruitment.
DSS patients appear representative of breast cancer patients
at large.
All 135 patients completed baseline assessments, with 117 (87%)
being assessed at all four time points. The completeness of
individual tests at each assessment time is generally high, except
for hepatic function tests, which were often overlooked, especially
at later assessments (Table 2).
Pulmonary function results
Overall 88% of all FEV1 results were classed as normal (Figure 1).
There was no indication in either treatment arm of a significant
time effect on normal FEV1 levels (P40.57), nor any differences
detected between treatments at each of the four time points
(P40.23).
Eighty one percent of all FVC results were classed as normal
(Figure 2A–C). In terms of the actual scores of the patients,
there was no significant linear change over time (P¼0.55)
and no difference between treatments in terms of their change
over time (P¼0.84). Individually for the treatment arms,
the populations’ FVC scores, predicted from linear modelling,
highlight the lack of differences over time and between treatments
(Figure 2C).
A total of 56% of all TLCO results were classed as normal
(Figure 2D–F). Individual patient scores show a slight reduction
in TLCO during treatment, which appears slightly more pro-
nounced in the EC-GT patients. The quadratic change over time
observed (Po0.0001) suggests that the reduced TLCO results
during treatment tend to recover 6-months post treatment. The
populations’ TLCO scores, predicted from quadratic modelling,
show a significantly lower drop in TLCO levels for EC-GT patients
(P¼0.02) (Figure 2F).
Dyspnoea was recorded as an AE during treatment in 32% of
patients (43 of 135) and 9% of all cycles. Dyspnoea was CTC grade
2 in 89% and grade 3 in 4% of abnormal cycles. It was ungraded in
the remaining 7%.
One hundred and twenty-two of the 135 DSS patients (90%)
received radiotherapy, 13 (10%) did not. 134 of the 135 DSS
patients (99%) have calculable chemotherapy course dose
intensity. Adjusting the analysis of the pulmonary function tests
by whether patients had received radiotherapy or not, and also
by their chemotherapy dose intensity did not affect findings.
Cardiac function
Overall 370 ECG, 323 echocardiogram and 168 MUGA results have
been reported. Two patients switched mode of assessment of LVEF
from initial to subsequent assessments: one from MUGA to echo
and one vice versa – neither of these patients had any suggestion of
cardiac dysfunction therefore they have been included in the
analysis.
The majority of patients have normal echocardiograms/MUGAs
(96% of patients at baseline, 97% at mid and 93% at end of
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schemotherapy, 94% at 6 months) and ECG’s (94% of patients at
baseline, 89% at mid and 96% at end of chemotherapy, 82% at
6 months (Figure 3A and B).
In 11 (8%) patients (6 EC-T; 5 EC-GT), ECHO/MUGA’s were
categorised as having changed from normal to abnormal through-
out treatment. In two patients (assessed by echocardiography)
LVEF value was not recorded. Of the remaining nine patients,
two increased LVEF by 2%. For the other seven, the mean
reduction in LVEF was 9% (range: 2–16%), with five patients
having LVEF below 50%. Four patients had a fall of LVEF 410%;
in three of these to o50%. The first abnormal test was the second
scan in three patients, the third in six patients and the fourth
in two patients. Three cardiac SAE’s were reported from two
patients: one patient experienced tachycardia mid-chemo-
therapy, the other asymptomatic reduction in LVEF (54–42%)
mid-chemotherapy and symptomatic CHF 1 month later. Post-
chemotherapy, LVEF returned to normal after this patient was
treated with the ACE inhibitor lisinopril. In 6 of 11 patients,
cardiac function testing recovered to normal at 6-month
post-chemotherapy. There was no significant change in ECHO/
MUGA cardiac function over time in either treatment arm
(P40.41) and no difference between treatments at any time point
(P40.36).
There was no difference in ECG results between treatments at
any time point (P40.27) and no difference within either treatment
arm over time (P40.12). The majority of the 34 possibly abnormal
ECG’s were minor ST-T wave changes (8), sinus brady/tachycardia
(6), left bundle branch block (3) and left atrial abnormality (2).
The ECG changed from normal to abnormal during treatment in
Table 1 Patient and tumour characteristics
ECGT (n¼69) ECT (n¼66)
N % N %
Age
p50 years old 38 55 36 55
450 years old 31 45 30 45
ER status
Negative 56 81 53 80
Weakly-positive 7 10 7 11
Positive 6 9 6 9
PgR status
Negative 43 62 34 52
Weakly-positive 7 10 10 15
Positive 2 3 2 3
Unknown 17 25 20 30
Nodal status
Negative 13 19 12 18
1–3 nodes positive 24 35 24 36
X4 nodes positive 32 46 30 46
HER2 status
+++ 11 16 9 14
Other (0, 1+, 2+) 17 25 14 21
Not measured 41 59 43 65
ECOG performance status
06 4 9 3 6 3 9 5
13 4 3 5
22 3 0 0
Menopausal status
Pre 33 48 27 41
Peri 5 7 5 8
Post 27 39 28 42
Hysterectomy 2 3 1 1
Unknown 2 3 5 8
Definitive surgery
Mastectomy 45 65 42 64
Breast conserving surgery 24 35 24 36
Definitive surgery to entry (days)
Median (IQR) 32 (24–42) 33 (21–39)
Range 11–57 15–56
Tumour diameter
p2cm 22 32 29 44
42 and p5cm 36 52 32 48
45cm 9 13 4 6
Unknown 2 3 1 2
Distance to closest radial margin
o1mm 5 7 2 3
1t oo5mm 10 15 15 23
5t oo10mm 12 17 6 9
X10mm 17 25 16 24
Unknown 25 36 27 41
Tumour type
a
Ductal/NST 63 91 61 92
Lobular 9 13 4 6
Tubular/Cribform 1 1 4 6
Medullary 1 1 1 1
Other 1 1 2 3
Unknown 1 1 0 0
Tumour grade
1 – Well differentiated 0 0 1 2
2 – Moderately differentiated 6 9 5 7
Table 1 (Continued)
ECGT (n¼69) ECT (n¼66)
N % N %
3 – Poorly differentiated 63 91 59 89
Unknown 0 0 1 2
Vascular/lymphatic invasion reported
Yes 48 70 36 55
No 21 30 30 45
Axillary nodes involved
Median (IQR) 3 (1–6) 3 (1–9)
Range 0–24 0–27
aSome specimens have multiple types.
Table 2 Completeness of assessments
N (%) of patients with test results
4 time
points
X3 time
points
X2 time
points
X1 time
point
No
results
Tests (N¼117) (N¼128) (N¼133) (N¼135) (N¼135)
FEV1 89 (76) 117 (91) 132 (99) 135 (100) 0 (0)
FVC 89 (76) 117 (91) 132 (99) 135 (100) 0 (0)
TLCO 85 (73) 109 (85) 130 (98) 135 (100) 0 (0)
ECHO/
MUGA
101 (86) 124 (97) 132 (99) 134 (99) 1 (1)
ECG 45 (38) 85 (66) 114 (86) 125 (93) 10 (7)
CXR 60 (51) 93 (73) 117 (88) 128 (95) 7 (5)
AST 30 (26) 57 (45) 84 (63) 94 (70) 41 (30)
ALT 26 (22) 55 (43) 82 (62) 104 (77) 31 (23)
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sonly 15 patients (8 EC-T and 7 EC-GT). Only two of these had ECG
changes suggestive of ischaemia, the others being minor ST-T
or rhythm changes. Only one of these patients was deemed
to have abnormal LVEF (55% on the first two echocardiograms
to 57% on the third, which was deemed to be abnormal and
52% on the fourth also abnormal). These data illustrate that
ECG’s alone are not a very useful tool for assessing safety of
chemotherapy.
At each time point, the majority of CXRs were classed as normal
(Figure 3C). At each time point, no differences were detected
between treatments (P40.44). There was also no indication in
either treatment arm of a time effect on CXRs (P40.11). In all 14
patients (9 EC-T; 5 EC-GT) developed abnormal CXRs. In three,
the CXR change was possible cardiomegaly/cardiac failure. Only
one of these patients had a corresponding change in LVEF
(increasing from 60% at baseline to 81%!) In two patients, changes
were because of infection, one of these with a reported suggestion
of pulmonary fibrosis. The reported possible pulmonary fibrosis at
6 months post-chemotherapy was, 2 months later, confirmed as
pulmonary metastases. The second patient with a reported possible
infection had reduced pulmonary function at the time of the
abnormal CXRs.
Hepatic function results
Overall 99% of baseline AST results and 94% of baseline ALT
results were normal (Figure 3D and E). Subsequent time points
showed normal rates drop slightly to 88% for AST and 75% for
ALT. Abnormal results were: grade 1¼42%, 2¼50% 3¼8% for
AST and grade 1¼64%, 2¼18% and 3¼18% for ALT. At three
time points, no treatment differences were detected (P40.99 AST,
P40.10 ALT). A higher abnormal rate was detected in EC-GT
patients at post-chemotherapy (P¼0.03 AST, P¼0.003 ALT).
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Figure 2 Pulmonary function levels over time (GREY dashed¼EC-T patients, BLACK solid¼EC-GT patients). (A) FVC levels. (B) FVC levels as percent
of patient baseline level. (C) Average FVC levels over time for each treatment arm, predicted by random effects model. (D)T L CO levels. (E)T L CO levels as
percent of patient baseline level. (F) Average TLCO levels over time for each treatment arm, predicted by random effects model.
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Figure 1 FEV1 results over the four time points.
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sThere was no change over time in EC-T patients (P¼0.09 AST,
P¼0.32 ALT) but a significant time effect in EC-GT patients
(P¼0.001 AST, Po0.0001 ALT) highlighting more abnormal levels
at mid- and post-chemotherapy time points.
AST became abnormal in 15 patients (six EC-T, nine EC-GT)
throughout treatment. In 13 patients with abnormal AST at
mid-chemotherapy, none required dose reductions and only two
dose delays (one in cycle 5 (reason not stated) and one in cycle 5
(for myelosuppression/neutropenia and oral/GI tract toxicity) and
cycle 6 (for infection)) during the second half of their treatment
regimen. All bar one patient received all their eight chemotherapy
cycles (one only receiving five cycles because of an allergic
reaction).
In 28 patients (8 EC-T, 20 EC-GT) ALT became abnormal during
treatment. 22 of these were at mid-chemotherapy. Seven had dose
reductions in the second half of their chemotherapy (13 cycles in
total). Main reasons were neuropathy, arthralgia and myalgia
(most commonly the latter two stated together). Three patients had
dose delays in the second half of their chemotherapy (three cycles
in total). The reasons were myelosupression/neutropenia, fatigue
and a not stated reason. All 22 patients received all their eight
chemotherapy cycles.
There was no association between elevated liver enzymes and
abnormal FEV, FVC or TLCO levels, nor ECHO/MUGA, ECG or
CXR results.
Acute skin toxicity results
One hundred twenty-two of the 135 patients (92%) received
radiotherapy. In 98 (83%) (45 EC-T, 53 EC-GT), weekly acute skin
toxicity was recorded. Toxicity was nil/mild in 87%, moderate
in 12% and severe in 1%. Skin toxicity increased with time in
each treatment arm (both Po0.0001, Figure 3F), but there was
no difference between the chemotherapy groups at any time
(P40.33).
Deaths
With a median follow-up of 48 months, 25 of 135 patients have
died (19%). None were attributable to tAnGo treatment.
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sDISCUSSION
The tAnGo trial addresses the addition of gemcitabine to a block
sequential anthracycline-taxane regimen for improvement of DFS.
Case reports and retrospective series describing a potential
problem of pulmonary toxicity from gemcitabine, particularly in
proximity to radiotherapy, led us to undertake a systematic
prospective quantitative substudy to assess pulmonary function by
FEV1/FVC measurement, and carbon monoxide diffusion tests.
Only TLCO was significantly affected by chemotherapy, with a
small reduction in both treatment arms, and more so with EC-GT.
The majority of this effect occurred during the EC chemotherapy.
Six months after treatment, TLCO had recovered in both arms.
The effect of anthracycline and cyclophosphamide on pulmon-
ary function has not been well documented until now. A significant
reduction in DLCO (see Appendix) has been demonstrated in
patients with lung cancer following carboplatin/gemcitabine (Maas
et al, 2003) or carboplatin/paclitaxel (Dimopoulou et al, 2002). In
the tAnGo DSS, we saw a significantly greater drop in TLCO levels
for EC-GT patients than EC-T patients (P¼0.02) but most of this
difference had emerged during the EC phase of treatment. By
the end of chemotherapy though, equal proportions of patients
on the treatment arms were classed as normal, and recovery for all
patients appeared complete by 6 months post-chemotherapy.
There was no increase in reported pulmonary AEs. A third of the
tAnGo DSS patients had dyspnoea recorded as an AE, in 9% of
cycles. The majority was CTC grade 2.
The rate of cardiac dysfunction in this substudy was comparable
with that in CALGB9344 (Henderson et al, 2003) where clinically
important cardiac dysrhythmias, congestive heart failure, changes
in LVEFs, or any other heart symptoms regardless of any possible
relationship to treatment occurred in up to 2% of patients during
treatment and was not significantly different between those who
did and those who did not receive paclitaxel. Congestive heart
failure was observed during protocol therapy in four (o1%) and
six (o1%) patients and during post-treatment follow-up in 23
(1%) and 27 (2%) patients randomly assigned to CA (four cycles of
cyclophosphamide 600mgm
 2 plus doxorubicin 60, 75 or
90mgm
 2) alone and CA plus paclitaxel (175mgm
 2), respec-
tively. In the NSABP-B28 trial (four cycles of cyclophosphamide
600mgm
 2 plus doxorubicin 60mgm
 2 followed by four cycles
paclitaxel 225mgm
 2 or no paclitaxel) the incidence of grade 3 or
higher cardiac dysfunction either during or subsequent to therapy
was 1.0% in the control and 0.9% in the experimental arm
(Mamounas et al, 2005). The variation in cardiac function in
different institutions involved in the tAnGo DSS was a noticeable
feature, as was the fact that some patients in whom echocardio-
graphy was recorded as abnormal were also shown to have
increased LVEF. Although recording of LVEF gives some useful
information, it must be remembered that, as with all tests, it has
limitations and does not substitute for appropriate liaison with
cardiologists when required.
Transient elevation of transaminases were seen in both
treatment groups of the tAnGo DSS with significantly more
abnormal levels in EC-GT patients post-chemotherapy (AST
P¼0.03, ALT P¼0.003, respectively), although the majority of
these were low grade. The effect of gemcitabine on transaminases
is well described and is a dose limiting toxicity at higher doses of
gemcitabine (Fossella et al, 1997). Liver enzymes returned to
normal by 6 months post-chemotherapy in all bar one EC-T
patient with an abnormal AST and four patients (2 EC-T, 2EC-GT)
with abnormal ALT levels. The long-term sequelae of disturbances
of transaminases are unknown. There was no correlation between
increases in liver enzymes and other toxicities, nor any difference
in received dose intensity between patients with and without
elevated liver enzymes during treatment (median dose intensity 96
and 98% respectively, P¼0.43).
Gemcitabine has been reported to give rise to a radiation recall
phenomenon when used in doses of 600mm
 2 and higher (Jeter
et al, 2002). However, the tAnGo DSS showed no exacerbation of
radiotherapy-related skin toxicity in EC-GT patients when
compared with EC-T patients.
The requirement for large adequately powered trials of adjuvant
treatment in breast cancer precludes comprehensive testing of all
patients for all potential side effects. The concept of detailed safety
substudies is well established in endocrine therapy trials (Eastell
et al, 2006; Coleman et al, 2007) and detailed toxicity monitoring
was performed in the CALGB9344 trial in which complete blood
counts were obtained two times weekly, and all toxicities of grade 2
or more were collected on the first 325 patients enrolled. After the
Data and Safety Monitoring Board reviewed this data, only
toxicities of grades 3 or higher were recorded (Henderson et al,
2003). In the 135 tAnGo DSS patients, there was good protocol
compliance especially with respect to the less standard procedures
of LVEF monitoring and pulmonary function testing, for which 97
and 91% of patients respectively had three or more of the required
tests and 86 and 76% respectively had all required time points.
Somewhat surprisingly what might be considered more routine
testing of transaminases was achieved less frequently.
In conclusion, the tAnGo DSS was undertaken to monitor the
introduction of gemcitabine into adjuvant chemotherapy regimen
for breast cancer. Both tAnGo treatments appear equally well
tolerated, only causing mild to modest reduction in pulmonary
function, which recovered completely by 6 months. Gemcitabine
caused increased transaminase abnormalities of no clinical
significance. This DSS clearly demonstrates that the addition of
Gemcitabine to paclitaxel after epirubicin and cyclophosphamide
for treatment of early breast cancer is safe. The DSS provides a
useful means of detailed safety assessment for the addition of new
agents into adjuvant treatment.
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Appendix
TLCO (reported in mlminkPa
 1) and DLCO (reported in
ml
 1min
 1mmHg) measure the same function and are related
by a conversion factor (TLCO¼0.335 DLCO).
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